期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

疟疾偶联疫苗 被引量：6

Malaria Conjugate Vaccine
下载PDF
导出
摘要 很多疟疾抗原在人体中是弱免疫原,化学偶联是一种提升弱免疫原免疫原性的方法,其价值已在疟疾疫苗的研究工作中得到证明。本文介绍了蛋白质偶联的一些常用化学连接剂和载体蛋白,并综述了疟疾偶联疫苗的研究进展。 Many malarial antigens are poor immunogens in human. Chemical conjugation is one of the ways to enhance the immunogenicity of those poor immunogens. Its value has been demonstrated in malaria vaccine research. This article introduces the chemical linkers and the carrier proteins, which are often used for protein conjugation, and summarizes the research progress in malarial conjugate vaccine development.
作者 钱锋 徐沪济
机构地区 第二军医大学长征医院风湿免疫科
出处 《中国寄生虫学与寄生虫病杂志》 CAS CSCD 北大核心 2012年第5期393-395,400,共4页 Chinese Journal of Parasitology and Parasitic Diseases
基金 国家重点基础研究发展计划(973计划)项目(No.2007-CB513105) 国家自然科学基金(No.81072498) 教育部留学回国人员科研启动基金~~
关键词 疟疾 化学偶联 疫苗 Malaria Chemical conjugation Vaccine
分类号 R531.3 [医药卫生—内科学]
  • 相关文献

参考文献24

  • 1Thiem VD, Lin FY, Canh do G, et al. The Vi conjugate iyphoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines[J]. Clin Vaccine Immunol, 2011, 18(5): 730-735.
  • 2Torafio G, Toledo ME, Baly A, et al. Phase I clinical evaluation of a synthetic oligosaccharide-protein conjugate vaccine against Haertu- philus influenzae type b in human adult volunteers [J]. Clin Vac- cine Immunol, 2006, 13(9): 1052-1056.
  • 3Br-ker M, Dull PM, Rappuoli R, et al. Chemistry of a new investiga- tional quadrivalent meningococcal conjugate vaccine that is im- munogenic at all ages [J]. Vaccine, 2009, 27(41): 5574-5580.
  • 4Poolman J, Frasch C, Nurkka A, et al. Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines [J]. Clin Vac- cine Immunol- 2011, 18(2): 327-336.
  • 5钱锋.不同的化学连接剂偶联恶性疟原虫Pfs25抗原和绿脓杆菌重组去毒外毒素rEPA[J].中国寄生虫学与寄生虫病杂志,2011,29(4):254-257. 被引量：6
  • 6Fass R, van de Walle M, Shiloach A, et al. Use of high densi- ty cultures of Escherichia coli for high level production of re- combinant Pseudomonas aeruginosa exotoxin A [J]. Appl Micro- biol Biotechnol, 1991, 36(1): 65-69.
  • 7Giannini G, Rappuoli R, Ratti G. The amino-acid sequence of two non-toxic mutants of diphtheria toxirr CRM45 and CRM197 [J]. Nu- cleic Acids Res, 1984, 12(10): 4063-4069.
  • 8Tsai CM, Frasch CE, Mocca LF. Five structural classes of major outer membrane proteins in Neisseria meningitidis [J]. J Bacteri-ol, 1981, 146(1): 69-78.
  • 9Pastan I, FitzGerald D. Pseudomonas exotoxin: chimeric toxins [J]. J Biol Chem, 1989, 264 (26): 15157-15160.
  • 10Fu J, Bailey FJ, King JJ, et al. Recent advances in the large scale fermentation of Neisseria meningitidis group B for the pro- duction of an outer membrane protein complex [J]. Nat Biotech- nol, 1995, 13(2): 170-174.

二级参考文献14

  • 1Kaslow DC, Quakyi IA, Syin C, et al. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains [J]. Nature, 1988, 333(6168): 74-76.
  • 2Stowers A, Carter R. Current developments in malaria transmission- blocking vaccines[J]. Expert Opin Biol Ther, 2001, 1(4): 619- 628.
  • 3Saul A. Mosquito stage, transmission blocking vaccines for malaria[J]. Curt Opin Infect Dis, 2007, 20(5): 476-481.
  • 4Kaslow DC, Quakyi IA, Keister DB. Minimal variation in a vaccine candidate from the sexual stage of Plasmodium falciparum [J]. Mol Biochem Parasitol, 1989, 32(1): 101-103.
  • 5Shi YP, Alpers MP, Povoa MM, et al. Single amino acid variation in the ookinete vaccine antigen from field isolates of Plasmodium falciparum [J]. Mol Biochem Parasitol, 1992, 50 (1): 179-180.
  • 6Wu Y, Przysiecki C, Flanagan E, et al. Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex[J]. Proc Natl Acad Sci USA, 2006, 103(48): 18243-18248.
  • 7Kubler-Kielb J, Majadly F, Wu Y, et al. Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25[J]. Proc Natl Acad Sci USA, 2007, 104(1): 293-298.
  • 8Qian F, Wu Y, Muratova O, et al. Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates[J]. Vaccine, 2007, 25(20): 3923-3933.
  • 9Qian F, Rausch KM, Muratova O, et al. Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders[J]. Vaccine, 2008, 26(20): 2521-2527.
  • 10Wu Y, Ellis RD, Shaffer D, et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51[J/OL]. PLoS One, 2008, 3(7): e2636. http ://www.plosone.org/article/info% 3Adoi% 2F10.1371% 2Fjournal. pone.0002636.

共引文献5

同被引文献176

  • 1曲莉,钱锋.疟疾疫苗研究进展[J].国外医学（寄生虫病分册）,2005,32(4):147-152. 被引量：2
  • 2刘德全.疟原虫的抗药性与抗疟药的合理应用[J].中国寄生虫学与寄生虫病杂志,2005,23(B10):355-361. 被引量：7
  • 3Cibulskis RE, Aregawi M, Williams R, et 01. Worldwide inci?dence of malaria in 2009: estimates, time trends, and a critique of methods[J]. PLoS Med, 2011, 8(12): e1OO1142.
  • 4Matsushita M, Fujita T. The role of ficolins in innate immunity[J]. Immunobiology, 2002, 205(4-5): 490-497.
  • 5Fujita T, Matsushita M, Endo Y. The lectin-complement pathway and its role in innate immunity and evolution[J]. Immunol Rev, 2004, 198( I): 185-202. .
  • 6Matsushita M, Endo Y, Taira S, et 01. A novel human serum lectin with collagen- and fibrinogen-like domains that functions as an opsonin[J].J BioI Chem, 1996, 271 (5): 2448-2454.
  • 7Fujimori Y, Harumiya S, Fukumoto Y, et 01. Molecular cloning and characterization of mouse ficolin-A[J]. Biochem Biophys Res Commun, 1998, 244(3): 796-800.
  • 8Ohashi T, Erickson HP. Oligomeric structure and tissue distribu?tion of ficolins from mouse, pig and human[J]. Arch Biochem Biophys, 1998, 360(2): 223-232.
  • 9Hirunpetcharat C, TianJH, Kaslow DC, et 01. Complete protec?tive immunity induced in mice by immunization with the 19- kilodalton carboxyl-terminal fragment of the merozoite surface protein-l (MSPl) of Plasmodium yoelii expressed in Saccha?rom.yces cerevisiae: correlation of protection with antigen-specific antibody titer, but not with effector CD4+T cells[J].J Immunol, 1997, 159(7): 3400-3411.
  • 10Matsushita M, Endo Y, Fujita T. Cutting edge: Complement-acti?vating complex of ficolin and mannose-binding lectin-associated serine protease[J].J Immunol, 2000, 164(5): 2281-2284.

引证文献6

中国寄生虫学与寄生虫病杂志
2012年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部